Galmed Pharmaceuticals Ltd.

As of June 30, 2026, Galmed Pharmaceuticals Ltd. carries a market capitalization of 557,074.37, placing it among publicly traded companies globally. Its enterprise value stands at -10.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Galmed Pharmaceuticals Ltd.'s next confirmed earnings release is scheduled for November 25, 2026.

As of June 30, 2026, Galmed Pharmaceuticals Ltd. has 125,174.00 shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Galmed Pharmaceuticals Ltd. maintains a current ratio of 4.16, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Galmed Pharmaceuticals Ltd. posted a negative return on equity (ROE) of -68.21, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -55.03, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 6.00, a quick read on workforce productivity versus industry peers.

As of the close on October 2, 2026, Galmed Pharmaceuticals Ltd.'s stock has declined approximately 71.26% over the past 52 weeks. The 50-day moving average sits at 4.11, while the 200-day moving average is 4.95.

Over the twelve months ended June 30, 2026, Galmed Pharmaceuticals Ltd. generated - - in revenue and converted that into -11.34M in net income, yielding earnings per share of -13.83. EBITDA reached -11.89M, while operating income came in at -9.96M.

As of June 30, 2026, Galmed Pharmaceuticals Ltd. holds 11.23M in cash and equivalents against 129,000.00 in total debt, resulting in a net debt position of -2.88M. Total book value stands at 12.74M, with working capital of 8.90M providing operational flexibility.

Galmed Pharmaceuticals Ltd. produced -8.54M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -234.00: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -481.08, meaning Galmed Pharmaceuticals Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Galmed Pharmaceuticals Ltd.'s most recent stock split took place on August 19, 2026 with a 8:1 split ratio.

As of June 30, 2026, Galmed Pharmaceuticals Ltd. has an Altman Z-Score of -27.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.